

**IN THE CLAIMS:**

Cancel claims 1-28 and 31-48. This leaves pending claims 29-30 and 49-69 as shown in the full listing of claims below.

Claims 1-28 (canceled)

1            Claim 29 (original): A layered tablet for the treatment of herpes simplex and  
2 conditions giving rise thereto, said layered tablet comprising an immediate-release layer and  
3 a sustained-release layer, and comprising the following as active ingredients distributed  
4 between said immediate-release layer and said sustained-release layer in the following  
5 approximate proportions expressed as relative weight percents:

|                            | <u>Immediate-Release Layer</u> | <u>Sustained-Release Layer</u> |
|----------------------------|--------------------------------|--------------------------------|
| Magnesium L-ascorbate      | 40-60%                         | balance                        |
| 2-Amino-2-deoxy-D-glucose  | 40-60%                         | balance                        |
| L-lysine monohydrochloride | 40-60%                         | balance                        |
| N-acetyl-L-cysteine        | 40-60%                         | balance                        |
| Quercetin                  | 40-60%                         | balance                        |
| L-Selenomethionine         | 100%                           |                                |
| Copper sulfate             | 100%                           |                                |
| Zinc picolinate            | 40-60%                         | balance                        |

1            Claim 30 (original): A layered tablet for use as an oral dosage form, said  
2 layered tablet comprising an immediate-release layer and a sustained-release layer, and  
3 comprising the following as active ingredients distributed between said immediate-release  
4 layer and said sustained-release layer in the following approximate proportions expressed as  
5 relative weight percents:

|                   | <u>Immediate-Release Layer</u> | <u>Sustained-Release Layer</u> |
|-------------------|--------------------------------|--------------------------------|
| Magnesium taurate | 40-60%                         | balance                        |

|                           |        |         |
|---------------------------|--------|---------|
| L-selenomethionine        | 100%   |         |
| 2-Amino-2-deoxy-D-glucose | 40-60% | balance |
| L-Lysine ascorbate        | 50-60% | balance |
| Copper sulfate            | 100%   |         |
| Zinc lysinate             | 40-60% | balance |
| N-acetyl-L-cysteine       | 40-60% | balance |
| Quercetin                 | 40-60% | balance |

6                    Claims 31-48 (canceled)

7                    Claim 49 (original): A unit dosage form for the treatment of herpes simplex  
8 and conditions giving rise thereto, said unit dosage form being a vaginal dosage form  
9 selected from the group consisting of vaginally appropriate suppositories, creams, tablets and  
10 gels, comprising as active ingredients:

- 11                    (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,  
12                    (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,  
13                    (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and  
14                    (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1                    Claim 50 (original): A unit dosage form in accordance with claim 49 further  
2 comprising as an active ingredient copper sulfate in a concentration ranging from about 0.4  
3 µg/mL to about 15 µg/mL.

1                    Claim 51 (original): A unit dosage form in accordance with claim 49 further  
2 comprising as an active ingredient quercetin in a concentration ranging from about 0.12  
3 µg/mL to about 2.75 µg/mL.

1                   Claim 52 (original): A unit dosage form in accordance with claim 49 further  
2 comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6  
3 unit/mL to about 8 units/mL.

1                   Claim 53 (original): A unit dosage form in accordance with claim 49 further  
2 comprising as an active ingredient quercetin in a concentration ranging from about 0.12  
3 µg/mL to about 2.75 µg/mL and heparin sodium in a concentration ranging from about 0.6  
4 unit/mL to about 8 units/mL.

1                   Claim 54 (original): A unit dosage form in accordance with claim 49 further  
2 comprising as an active ingredient quercetin in a concentration ranging from about 0.12  
3 µg/mL to about 2.75 µg/mL, heparin sodium in a concentration ranging from about 0.6  
4 unit/mL to about 8 units/mL, and N-acetylcysteine in a concentration ranging from about 0.6  
5 units/mL to about 8 units/mL.

1                   Claim 55 (original): A unit dosage form for the treatment of herpes simplex  
2 and conditions giving rise thereto, said unit dosage form being a mucosal dosage form  
3 selected from the group consisting of vaginally appropriate suppositories, creams, tablets and  
4 gels, comprising as active ingredients:

- 5                   (a) ascorbic acid,  
6                   (b) 2-amino-2-deoxy-D-glucose,  
7                   (c) zinc sulfate, and  
8                   (d) L-lysine hydrochloride.

1                   Claim 56 (original): A unit dosage form in accordance with claim 55 in which  
2 the concentrations of said active ingredients are as follows:

- 3                   (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,  
4                   (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,

- 5 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and  
6 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 Claim 57 (original): A unit dosage form in accordance with claim 55 further  
2 comprising as an active ingredient copper sulfate in a concentration ranging from about 0.4  
3 µg/mL to about 15 µg/mL.

1 Claim 58 (original): A unit dosage form in accordance with claim 55 further  
2 comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6  
3 units/mL to about 8 units/mL.

1 Claim 59 (original): A unit dosage form in accordance with claim 55 further  
2 comprising as active ingredients copper sulfate in a concentration ranging from about 0.4  
3 µg/mL to about 15 µg/mL and heparin sodium in a concentration ranging from about 0.6  
4 units/mL to about 8 units/mL.

1 Claim 60 (original): A unit dosage form in accordance with claim 55 further  
2 comprising as an active ingredient N-acetyl-L-cysteine in a concentration ranging from about  
3 0.02 mg/mL to about 0.5 mg/mL.

1 Claim 61 (original): A unit dosage form in accordance with claim 55 further  
2 comprising as an active ingredient L-2-oxothiazolidine-4-carboxylate in a concentration  
3 ranging from about 0.02 mg/mL to about 0.5 mg/mL.

1 Claim 62 (original): A unit dosage form for the treatment of herpes simplex  
2 and conditions giving rise thereto, said unit dosage form being a topical dermal dosage form  
3 selected from the group consisting of topical lotions, gels, creams, and emulsions, comprising  
4 as active ingredients:

- 5 (a) ascorbic acid,  
6 (b) 2-amino-2-deoxy-D-glucose,

- 7 (c) zinc sulfate, and  
8 (d) L-lysine hydrochloride.

1 Claim 63 (original): A unit dosage form in accordance with claim 62 in which  
2 the concentrations of said active ingredients are as follows:

- 3 (a) about 1.3 µg/mL to about 30 µg/mL of ascorbic acid,  
4 (b) about 0.01 mg/mL to about 0.2 mg/mL of 2-amino-2-deoxy-D-glucose,  
5 (c) about 0.06 µg/mL to about 8.5 µg/mL of zinc sulfate, and  
6 (d) about 1.6 µg/mL to about 23 µg/mL of L-lysine hydrochloride.

1 Claim 64 (original): A unit dosage form in accordance with claim 63 further  
2 comprising as an active ingredient  $\text{Cu}^{+2}$  in a concentration ranging from about 0.15 µg/mL to  
3 about 15 µg/mL.

1 Claim 65 (original): A unit dosage form in accordance with claim 64 further  
2 comprising as an active ingredient quercetin in a concentration ranging from about 0.12  
3 µg/mL to about 2.75 µg/mL.

1 Claim 66 (original): A unit dosage form in accordance with claim 65 further  
2 comprising as an active ingredient heparin sodium in a concentration ranging from about 0.6  
3 unit/mL to about 8 units/mL.

1 Claim 67 (original): A unit dosage form in accordance with claim 66 further  
2 comprising as an active ingredient D,α-tocopherol in a concentration ranging from about 16  
3 µg/mL to about 1600 µg/mL.

1 Claim 68 (original): A unit dosage form in accordance with claim 67 in which  
2 said D,α-tocopherol is in the form of D,α-tocopherol nicotinate in a concentration ranging  
3 from about 19 µg/mL to about 2600 µg/mL.

- 1                    Claim 69 (original): A unit dosage form in accordance with claim 67 in which
- 2    said D, $\alpha$ -tocopherol is in the form of D, $\alpha$ -tocopherol succinate in a concentration ranging
- 3    from about 19  $\mu\text{g/mL}$  to about 2500  $\mu\text{g/mL}$ .